Table 1.
The grade of PBF expressioni and the progonosis in 83 patients with osteosarcoma
| Patients | Age | Gender | Location | Surgical stage | Histological type | Chemotherapy | Histological response grade | Operation | PBF expression | EFS (months) | OS (months) | Prognosis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 15 | M | Femur | IIB | Osteoblastic | T‐12 | 2 | Amputation | High | 39 | 46 | DOD |
| 2 | 20 | M | Humerus | IIB | Osteoblastic | T‐12 | 0 | Amputation | Low | 12 | 24 | DOD |
| 3 | 9 | F | Femur | IIB | Chondroblastic | T‐12 | 0 | WE+FVFG | High | 14 | 22 | DOD |
| 4 | 12 | M | Femur | IIB | Osteoblastic | T‐12 | 0 | Amputation | Low | 3 | 9 | DOD |
| 5 | 10 | F | Humerus | IIB | Teleangiectatic | T‐12 | 1 | WE+FVFG | High | 103 | 103 | CDF |
| 6 | 17 | F | Humerus | IIB | Osteoblastic | T‐12 | 2 | WE+FVFG | Low | 97 | 97 | CDF |
| 7 | 14 | F | Femur | IIB | Fibroblastic | NSH‐7 | 2 | WE+FVFG | Negative | 119 | 119 | CDF |
| 8 | 14 | M | Fibula | IIB | Chondroblastic | NSH‐7 | 2 | WE | High | 34 | 102 | NED |
| 9 | 11 | F | Tibia | IIB | Osteoblastic | NSH‐7 | 2 | WE+FVFG | Negative | 117 | 117 | CDF |
| 10 | 42 | F | Tibia | IIB | Osteoblastic | NSH‐7 | 2 | WE+Prosthesis | High | 72 | 72 | CDF |
| 11 | 14 | M | Tibia | IIB | Osteoblastic | NSH‐7 | 3 | WE+FVFG | High | 32 | 96 | NED |
| 12 | 18 | M | 2nd rib | IIB | Osteoblastic | NSH‐7 | 0 | WE | High | 106 | 106 | CDF |
| 13 | 33 | M | Pelvis | IIB | Chondroblastic | NECO93J | 1 | WE+FVFG | High | 8 | 13 | DOD |
| 14 | 20 | M | Femur | IIB | Fibroblastic | NECO93J | 2 | WE+FVFG | High | 72 | 72 | CDF |
| 15 | 15 | M | Femur | IIB | Osteoblastic | NECO93J | 2 | WE+FVFG | High | 106 | 106 | CDF |
| 16 | 15 | M | Femur | IIB | Osteoblastic | NECO93J | 2 | WE+FVFG | High | 20 | 33 | DOD |
| 17 | 20 | F | Femur | IIB | Osteoblastic | Not done† | (–)† | Not done† | Negative | 0 | 7 | DOD |
| 18 | 16 | M | Tibia | IIB | Chondroblastic | NECO93J | 2 | WE+FVFG | High | 6 | 6 | DOC‡ |
| 19 | 14 | F | Femur | IIB | Osteoblastic | NECO93J | 2 | WE | Negative | 5 | 5 | DOC‡ |
| 20 | 15 | M | Fibula | IIB | Osteoblastic | NECO93J | 0 | Amputation | High | 13 | 74 | DOD |
| 21 | 13 | M | Humerus | IIB | Chondroblastic | NECO93J | 0 | Amputation | High | 7 | 9 | DOD |
| 22 | 7 | F | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+FVFG | High | 85 | 85 | CDF |
| 23 | 10 | F | Tibia | IIB | Osteoblastic | NECO95J | 2 | Amputation | Negative | 72 | 72 | CDF |
| 24 | 13 | M | Femur | IIB | Osteoblastic | NECO95J | 0 | WE+RP | Low | 6 | 11 | DOD |
| 25 | 27 | M | Tibia | IIB | Osteoblastic | NECO95J | 0 | WE+FVFG | High | 8 | 18 | DOD |
| 26 | 18 | F | Femur | IIIB | Fibroblastic | NECO95J | 1 | WE+Prosthesis | High | 0 | 16 | DOD |
| 27 | 20 | F | Humerus | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | Negative | 67 | 67 | CDF |
| 28 | 69 | F | Femur | IIB | Fibroblastic | NECO95J | 0 | WE+Prosthesis | Low | 62 | 63 | NED |
| 29 | 15 | F | Femur | IIB | Osteoblastic | NECO95J | 3 | WE+FVFG | High | 32 | 32 | CDF |
| 30 | 46 | M | Pelvis | IIB | Fibroblastic | NECO95J | 0 | WE+Fillet | Low | 47 | 60 | NED |
| 31 | 40 | F | Femur | IIB | Fibroblastic | NECO95J | 2 | Amputation | Low | 12 | 20 | DOD |
| 32 | 19 | M | Tibia | IIB | Osteoblastic | NECO95J | 2 | Amputation | High | 41 | 43 | DOD |
| 33 | 15 | F | Femur | IIB | Fibroblastic | NECO95J | 3 | WE+FVFG | High | 52 | 52 | CDF |
| 34 | 48 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | Amputation | High | 17 | 37 | DOD |
| 35 | 15 | F | Femur | IIIB | Chondroblastic | NECO95J | 1 | WE+FVFG | High | 0 | 17 | NED |
| 36 | 42 | F | Sacrum | IIB | Osteoblastic | NECO95J | (–)§ | Not done§ | High | 0 | 18 | NED |
| 37 | 7 | M | Tibia | IIB | Osteoblastic | CCCH2 | 1 | WE+RP | Low | 13 | 86 | DOD |
| 38 | 12 | F | Femur | IIB | Chondroblastic | CCCH2 | 0 | Amputation | Low | 5 | 84 | DOD |
| 39 | 17 | M | Tibia | IIB | Chondroblastic | CCCH2 | 1 | WE+RP | High | 180 | 180 | CDF |
| 40 | 14 | F | Femur | IIB | Fibroblastic | CCCH2 | 0 | WE+Prosthesis | High | 13 | 167 | NED |
| 41 | 19 | M | Tibia | IIB | Fibroblastic | CCCH2 | 0 | WE+RP | Low | 20 | 36 | DOD |
| 42 | 14 | F | Tibia | IIB | Osteoblastic | CCCH2 | 0 | WE+Prosthesis | Low | 19 | 44 | DOD |
| 43 | 12 | M | Tibia | IIB | Osteoblastic | CCCH2 | 2 | WE+Prosthesis | High | 167 | 167 | CDF |
| 44 | 22 | M | Femur | IIB | Fibroblastic | NECO93J | 3 | WE+RP | Low | 164 | 164 | CDF |
| 45 | 21 | M | Femur | IIB | Chondroblastic | NECO93J | 1 | WE+RP | High | 34 | 80 | DOD |
| 46 | 20 | M | Tibia | IIB | Osteoblastic | NECO93J | 1 | WE+RP | High | 37 | 131 | NED |
| 47 | 17 | M | Femur | IIB | Osteoblastic | NECO93J | 3 | WE+FVFG | High | 127 | 127 | CDF |
| 48 | 8 | F | Humerus | IIB | Osteoblastic | NECO93J | 3 | WE+FVFG | Low | 126 | 126 | CDF |
| 49 | 20 | F | Humerus | IIB | Fibroblastic | NECO93J | 1 | WE+FVFG | High | 126 | 126 | CDF |
| 50 | 16 | F | Femur | IIB | Osteoblastic | NECO93J | 2 | WE+RP | High | 124 | 124 | CDF |
| 51 | 18 | M | Tibia | IIB | Osteoblastic | NECO93J | 0 | WE+RP | Low | 10 | 15 | DOD |
| 52 | 13 | F | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+Prosthesis | Low | 100 | 100 | CDF |
| 53 | 11 | M | Tibia | IIB | Chondroblastic | NECO93J | 2 | WE+RP | High | 121 | 121 | CDF |
| 54 | 12 | F | Tibia | IIB | Osteoblastic | NECO95J | 1 | WE+Prosthesis | High | 114 | 114 | CDF |
| 55 | 24 | M | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+Prosthesis | Negative | 79 | 79 | CDF |
| 56 | 14 | F | Humerus | IIB | Chondroblastic | NECO95J | 1 | WE+FVFG | High | 29 | 96 | NED |
| 57 | 26 | M | Tibia | IIB | Osteoblastic | NECO95J | 0 | WE+Prosthesis | High | 89 | 89 | CDF |
| 58 | 17 | M | Radius | IIB | Osteoblastic | NECO95J | 1 | WE+FVFG | Low | 84 | 84 | CDF |
| 59 | 18 | F | Femur | IIB | Chondroblastic | NECO95J | 1 | WE+Prosthesis | High | 17 | 69 | DOD |
| 60 | 15 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | Low | 75 | 75 | CDF |
| 61 | 17 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | Low | 74 | 74 | CDF |
| 62 | 13 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | Low | 72 | 72 | CDF |
| 63 | 11 | F | Femur | IIB | Osteoblastic | NECO95J | 3 | WE+Prosthesis | Low | 66 | 66 | CDF |
| 64 | 13 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | High | 65 | 65 | CDF |
| 65 | 13 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | Negative | 57 | 57 | CDF |
| 66 | 19 | F | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+Prosthesis | High | 54 | 54 | CDF |
| 67 | 24 | M | Tibia | IIB | Fibroblastic | NECO95J | 0 | WE+Prosthesis | Low | 45 | 45 | CDF |
| 68 | 14 | F | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | High | 48 | 48 | CDF |
| 69 | 15 | F | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+Prosthesis | Low | 7 | 18 | DOD |
| 70 | 19 | M | Radius | IIB | Osteoblastic | NECO95J | 1 | WE+FVFG | Low | 27 | 35 | NED |
| 71 | 16 | F | Fibula | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | Low | 33 | 33 | CDF |
| 72 | 10 | M | Tibia | IIB | Osteoblastic | NECO95J | 2 | Amputation | High | 12 | 32 | AWD |
| 73 | 11 | M | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+FVFG | Low | 31 | 31 | CDF |
| 74 | 29 | F | Fibula | IIB | Osteoblastic | NECO95J | 1 | WE | High | 25 | 25 | CDF |
| 75 | 10 | M | Femur | IIB | Chondroblastic | NECO95J | 0 | WE+Prosthesis | High | 9 | 20 | DOD |
| 76 | 8 | M | Femur | IIB | Osteoblastic | NECO95J | 1 | WE+RP | High | 6 | 19 | AWD |
| 77 | 20 | F | Tibia | IIB | Osteoblastic | NECO95J | 2 | Amputation | High | 16 | 16 | CDF |
| 78 | 12 | M | Femur | IIB | Osteoblastic | NECO95J | 3 | WE+Prosthesis | Low | 15 | 15 | CDF |
| 79 | 65 | M | Tibia | IIB | Osteoblastic | NECO95J¶ | (–)§ | WE+Prosthesis | High | 2 | 13 | NED |
| 80 | 20 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | High | 12 | 12 | CDF |
| 81 | 16 | M | Ilium | IIB | Osteoblastic | NECO95J | 1 | WE | High | 13 | 13 | CDF |
| 82 | 12 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | Amputation | High | 8 | 13 | DOD |
| 83 | 20 | M | Femur | IIB | Osteoblastic | NECO95J | 2 | WE+Prosthesis | High | 12 | 12 | CDF |
†
Chemotherapy and operation were refused by the patient and her family.
‡
‡Died of acute hepatitis B during postoperative chemotherapy.
§
§Carbon ion radiotherapy was chosen instead of operation.
¶
¶Chemotherapy was instituted only postoperatively. AWD, alive with disease; CDF, continuously disease free; DOC, death of other cause; DOD, death of disease; EFS, event‐free survival; F, female, FVFG, free vascularized fibula graft; M, male; NED, no evidence of disease; OS, overall survival; RP, rotational plasty; PBF, papillomavirus binding factor; WE, wide excision.